PHERGAIN
CHEMOTHERAPY-FREE TRASTUZUMAB AND PERTUZUMAB IN HER2-POSITIVE (HUMAN EPIDERMAL RECEPTOR) BREAST CANCER: FDG-PET RESPONSE-ADAPTED STRATEGY. THE PHERGAIN STUDY
CLINICAL TRIAL DETAILS
THE STUDY ASSESS THE EARLY METABOLIC EFFECTS OF NEOADJUVANT TREATMENT WITH TRASTUZUMAB AND PERTUZUMAB (± ENDOCRINE THERAPY) ON THE PRIMARY TUMOR AND AXILLARY LYMPH NODES AND THEIR PREDICTIVE VALUE FOR PATHOLOGIC COMPLETE RESPONSE (PCR) IN THE BREAST AND AXILLA.
AND ALSO ASSESS 3-YEAR INVASIVE DISEASE-FREE SURVIVAL (IDFS) IN PATIENTS WITH HER2-POSITIVE (HER: HUMAN EPIDERMAL RECEPTOR) BREAST CANCER TREATED WITH NEOADJUVANT TRASTUZUMAB AND PERTUZUMAB (± ENDOCRINE THERAPY) USING A FDG-PET RESPONSE-ADAPTED STRATEGY.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
HER2+ EBC
56
377
II
Spain, Portugal, France, UK, Italy, Belgium, Germany
Analysis
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
ESMO Breast 2026 Substudy PHERGuide
ASCO 2024 PHERGain MRI vs PET poster
ASCO 2024 MRI vs PET lay summary
AACR 2024 Substudy METSGain lay summary
AACR 2024 Substudy METSGain poster
ESMO 2023 Substudy HER2DX poster
ESMO 2023 Substudy Trop-2 poster
BLOG ARTICLES RELATED
Phergain Collaborators’ Ecosystem in Spain
Advancing Oncology Care: MEDSIR at ASCO Annual Meeting
Revolutionizing Patient Care: MEDSIR’s Hope for HER2-Positive Early Breast Cancer
We’re presenting at ESMO Breast Cancer 2022!
MEDSIR’s On Site Experience from SABCS 2021: Update on our 5 studies presented
Dr. José Manuel Pérez Discusses Advances in Treatment Options for HER2+ Breast Cancer
PHERGAIN clinical trial suggests F-PET can identify early HER2-positive breast cancer patients
MedSIR to present results of clinical trials PHERGain and PARSIFAL at ASCO 2020
100% Recruitment Achieved of PHERGain study!
Another big step in PHERGAIN Study
TRIAL SITES